Search Result

Results for "

ligand-binding

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FKBP (2) Ligands for Target Protein for PROTAC (1) Adrenergic Receptor (1) Androgen Receptor (5) Apoptosis (3) Aryl Hydrocarbon Receptor (1) Bcl-2 Family (1) Biochemical Assay Reagents (5) Cannabinoid Receptor (1) Cytochrome P450 (2) EGFR (2) Endogenous Metabolite (3) Ephrin Receptor (2) Estrogen Receptor/ERR (12) Ferroptosis (5) Fluorescent Dye (1) GABA Receptor (1) Glycosidase (2) Histamine Receptor (1) Histone Methyltransferase (6) IGF-1R (1) iGluR (3) Integrin (1) Interleukin Related (1) Isotope-Labeled Compounds (2) LOX-1 (1) MDM-2/p53 (1) nAChR (1) Nuclear Hormone Receptor 4A/NR4A (6) Orphan Receptor (2) Parasite (6) PPAR (12) PROTACs (9) RAR/RXR (1) ROR (2) SNIPERs (3) TGF-beta/Smad (1) TNF Receptor (2) Transmembrane Glycoprotein (1) TSH Receptor (1) UGT (1) VD/VDR (2)
By Research Areas:	Cancer (34) Cardiovascular Disease (1) Endocrinology (5) Infection (6) Inflammation/Immunology (14) Metabolic Disease (17) Neurological Disease (12)

By Targets:

FKBP (2)

Ligands for Target Protein for PROTAC (1)

Adrenergic Receptor (1)

Androgen Receptor (5)

Apoptosis (3)

Aryl Hydrocarbon Receptor (1)

Bcl-2 Family (1)

Biochemical Assay Reagents (5)

Cannabinoid Receptor (1)

Cytochrome P450 (2)

EGFR (2)

Endogenous Metabolite (3)

Ephrin Receptor (2)

Estrogen Receptor/ERR (12)

Ferroptosis (5)

Fluorescent Dye (1)

GABA Receptor (1)

Glycosidase (2)

Histamine Receptor (1)

Histone Methyltransferase (6)

IGF-1R (1)

iGluR (3)

Integrin (1)

Interleukin Related (1)

Isotope-Labeled Compounds (2)

LOX-1 (1)

MDM-2/p53 (1)

nAChR (1)

Nuclear Hormone Receptor 4A/NR4A (6)

Orphan Receptor (2)

Parasite (6)

PPAR (12)

PROTACs (9)

RAR/RXR (1)

ROR (2)

SNIPERs (3)

TGF-beta/Smad (1)

TNF Receptor (2)

Transmembrane Glycoprotein (1)

TSH Receptor (1)

UGT (1)

VD/VDR (2)

By Research Areas:

Cancer (34)

Cardiovascular Disease (1)

Endocrinology (5)

Infection (6)

Inflammation/Immunology (14)

Metabolic Disease (17)

Neurological Disease (12)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Antibodies

Targets Recommended: Emopamil Binding Protein Target Protein Ligand-Linker Conjugates Penicillin-binding protein (PBP) E3 Ligase Ligand-Linker Conjugates ATP-binding cassette (ABC) transporters Oxysterol-binding Protein-related Protein (ORP) FKBP FABP Transthyretin (TTR) Ligands for Target Protein for PROTAC PD-1/PD-L1 YB-1 SDCBP GHR P-glycoprotein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13956S

Pioglitazone-d4 U 72107-d₄	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone-d₄ is a deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively[1].

HY-13956

Pioglitazone Maximum Cited Publications 31 Publications Verification U 72107	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .

HY-N4194

Glabrone	PPAR	Metabolic Disease
Glabrone is an isoflavone isolated from Glycyrrhiza glabra roots. Glabrone exhibits anti-influenza activity and significant PPAR-γ ligand-binding activity .

HY-136242

UT-34	Estrogen Receptor/ERR	Endocrinology Cancer
UT-34 is a potent, selective, orally bioactive second-generation pan-androgen receptor (AR) antagonist and degrader, with IC₅₀ values of 211.7 nM, 262.4 nM, and 215.7 nM for wild-type AR, F876L-AR, and W741L-AR, respectively. UT-34 binds to the ligand-binding domain (LBD) and functional 1 (AF-1) domain of AR and requires the ubiquitin-proteasome pathway for AR degradation. UT-34 has anti-prostate cancer effects.

HY-P10579

123B9	Ephrin Receptor	Cancer
123B9, a tumor-homing agent, is a potent and selective EphA2 agonist with a K_d value of 4.0 μM. 123B9 selectively targets the EphA2 tyrosine kinase receptor ligand-binding domain. 123B9 does not appreciably inhibit the ligand binding domains of the most closely related EphA3 and EphA4 receptors .

HY-13956B

Pioglitazone potassium U 72107 potassium	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone (U 72107) potassium is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 μM and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone potassium can be used in diabetes research .

HY-13956C

(R)-Pioglitazone (R)-U 72107	PPAR	Neurological Disease
(R)-Pioglitazone ((+)-pioglitazone) is the R enantiomer of Pioglitazone (HY-13956). (R)-Pioglitazone is an orally active and selective peroxisome proliferator-activated receptor (PPARγ) agonist with high affinity binding to the PPARγ ligand-binding domain. (R)-Pioglitazone can be used for the research of Alzheimer's disease .

HY-13956R

Pioglitazone (Standard)	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone (Standard) is the analytical standard of Pioglitazone. This product is intended for research and analytical applications. Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .

HY-N11773

Gancaonin L	PPAR	Metabolic Disease
Gancaonin L is an isoflavone, that can be isolated from Glycyrrhiza glabra roots. Gancaonin L exhibits significant PPAR-γ ligand-binding activity. Gancaonin L can be used for anti-diabetes and anti-obesity research .

HY-116205

UBP684	iGluR	Others
UBP684 is a novel positive allosteric modulator of NMDA receptors (NMDARs) that enhances receptor function by stabilizing the ligand-binding domains in a closed conformation, resulting in potentiated whole-cell currents and increased mean open time.

HY-108822

Rilonacept Arcalyst; IL 1 Trap; Interleukin 1 Trap	Interleukin Related	Inflammation/Immunology
Rilonacept (Arcalyst), a dimeric fusion protein, is a interleukin 1 inhibitor. Rilonacept consists of the ligand-binding domains of the extracellular portions of the IL-1R components linked to the Fc portion of human IgG1. Rilonacept can be used for the research of cryopyrin-associated periodic syndromes .

HY-P99446

Atacicept TACI-Ig; TACI-Fc 5	TNF Receptor	Inflammation/Immunology
Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease .

HY-P10430

Stalk peptide	Transmembrane Glycoprotein	Neurological Disease
Stalk peptide is a GPR110 activator. Stalk peptide is released from GPCR Autoproteolysis INducing domain by autocatalytic process and then Stalk peptide is inserted into the ligand-binding pocket of the receptor to activate the receptor. Stalk peptide can promote nerve growth and synaptic formation. Stalk peptide can be used to study neurodevelopmental and neurodegenerative diseases .

HY-13956S1

Pioglitazone-d4 (alkyl)	Isotope-Labeled Compounds PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone-d₄ (alkyl) (U 72107-d4 (alkyl)) is the deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively[1][2].

HY-162738

JMV6944	Cytochrome P450 Ligands for Target Protein for PROTAC	Cancer
JMV6944 is a PXR agonist. JMV6944 competitively inhibits hPXR ligand-binding domain (LBD) binding to PXR with an IC₅₀ of 680nM. JMV6944 induces CYP3A4 mRNA expression in freshly isolated human primary human hepatocyte cultures. JMV6944 can be used for the synthesis of PROTAC PXR degrader JMV7048 (HY-162704) .

HY-111254

GQ-16	PPAR	Metabolic Disease
GQ-16 is a moderate affinity ligand for the ligand-binding domain (LBD) of PPARγ, exhibiting a K_i of 160 nM. GQ-16 is an effective inhibitor of Cdk5-mediated phosphorylation of PPARγ. GQ-16 is a partial agonist of PPARγ with reduced adipogenic actions. GQ-16 promotes insulin Sensitization without weight gain .

HY-170874

PPARγ modulator-2	PPAR	Metabolic Disease
PPARγ modulator-2 (Compound (R)-2n) is the reversible modulator for PPARγ that inhibits PPARγ ligand-binding domain (LBD) with an IC₅₀ of 41 nM. PPARγ modulator-2 reduces blood glucose, improves the glucose tolerance and insulin tolerance, and exhibits anti-diabetic efficacy in db/db mouse models .

HY-121372

Lactandrate	Estrogen Receptor/ERR	Cancer
Lactandrate is a D-high nitrogen steroid alkylating agent. It can interact with the ligand-binding domain (LBD) of estrogen receptor-alpha (ERα). Lactandrate has a growth inhibitory effect on breast cancer cells, with a GI₅₀ value ranging from 5 to 65 μM. It shows anti-tumor activity in mouse breast tumors (MXT and CD8F1) as well as in human xenograft MX-1 .

HY-117182

LG190178	Apoptosis VD/VDR RAR/RXR	Metabolic Disease Inflammation/Immunology Cancer
LG190178 is a non-steroidal vitamin D receptor (VDR) ligand that can induce the formation of heterodimer complexes between VDR and retinoid X receptor (RXR), stabilizing the agonistic conformation of the VDR ligand-binding domain and promoting its interaction with co-activators. LG190178 has functions in regulating calcium homeostasis, bone mineralization, as well as cell proliferation, differentiation, and apoptosis, making it useful for research in psoriasis, osteoporosis, and cancer .

HY-132205

DS45500853	Estrogen Receptor/ERR	Metabolic Disease
DS45500853 is an estrogen-related receptor α (ERRα) agonist. DS45500853 inhibits the binding between receptor-interacting protein 140 (RIP140) corepressor peptide (10 nM) and GST-ERRα ligand-binding domain (LBD; 1.2 μM) with an IC₅₀ value of 0.80 μM. DS45500853 can be used for the research of metabolic disorders, including type 2 diabetes mellitus (T2DM) .

HY-122742

HBT1	iGluR	Neurological Disease
HBT1 is a potent α-Amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor (AMPA-R) potentiator. HBT1 bonds with S518 in the ligand-binding domain (LBD) of AMPA-R in a glutamate-dependent manner. HBT1 did not show remarkable bell-shaped response in brain-derived neurotrophic factor (BDNF) production in primary neurons .

HY-P2264

KYL peptide	Ephrin Receptor	Inflammation/Immunology
KYL peptide, an antagonistic peptide, selectively targets EphA4 receptor (IC₅₀:4.22 μM, Kd:1.3 μM). KYL peptide binds to the ligand-binding domain of EphA4, effectively alleviates Aβ-induced synaptic dysfunction and synaptic plasticity defects in AD mice. KYL peptide can promote nerve regeneration after injury and modulating immune responses .

HY-143201

DS20362725	Estrogen Receptor/ERR	Metabolic Disease
DS20362725 is an estrogen-related receptor α (ERRα) agonist. DS20362725 inhibits the binding between receptor-interacting protein 140 (RIP140) corepressor peptide (10 nM) and GST-ERRα ligand-binding domain (LBD; 1.2 μM) with an IC₅₀ value of 0.6 μM. DS20362725 can be used for the research of metabolic disorders, including type 2 diabetes mellitus (T2DM) .

HY-N2025

Oroxin A	PPAR Glycosidase	Metabolic Disease
Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial PPARγ agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity . Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence .

HY-160250

UGT1A1-IN-1	UGT	Metabolic Disease
UGT1A1-IN-1 (compound 2) is a non-competitive inhibitor of UGT1A1, which can inhibit the 1-O-glucuronidation process mediated by UGT1A1 with a K_i value of 5.02 μM. UGT1A1-IN-1 (compound 2) can bind on UGT1A1 at the same ligand-binding site as bilirubin (HY-N0323). UGT1A1-IN-1 can serve as a ‘turn-on’ fluorescent probe substrate for UGT1A1 .

HY-N2025R

Oroxin A (Standard)	PPAR Glycosidase	Metabolic Disease
Oroxin A (Standard) is the analytical standard of Oroxin A. This product is intended for research and analytical applications. Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial PPARγ agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity . Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence .

HY-156190

NR2F2-IN-1	Orphan Receptor	Cancer
NR2F6 modulator-2 (CIA1) is a potent and selective orphan nuclear receptor COUP-TFII (NR2F2) inhibitor. NR2F6 modulator-2 substantially inhibits COUP-TFII–driven NGFIA reporter expression. NR2F6 modulator-2 directly binds to the COUP-TFII ligand-binding domain and disrupts COUP-TFII interaction with transcription regulators, including FOXA1, thus repressing COUP-TFII activity on target gene regulation .

HY-156190A

NR2F2-IN-1 free base	Orphan Receptor	Cancer
NR2F2-IN-1 (free base) is a potent and selective orphan nuclear receptor COUP-TFII (NR2F2) inhibitor. NR2F2-IN-1 (free base) substantially inhibits COUP-TFII–driven NGFIA reporter expression. NR2F2-IN-1 (free base) directly binds to the COUP-TFII ligand-binding domain and disrupts COUP-TFII interaction with transcription regulators, including FOXA1, thus repressing COUP-TFII activity on target gene regulation .

HY-103513

GABAA receptor agent 2	GABA Receptor	Others
GABAA receptor agent 2 (compound 13) is a compound used to study the structure and orthosteric ligand binding of GABA(A) receptors. The relevant model of GABAA receptor agent 2 can be used to understand the details of orthosteric ligand binding, and a detailed binding mode hypothesis was created through structure-activity relationships with two homologous series of orthosteric GABA(A)R antagonists.

HY-101601

Bamirastine TAK-427	Histamine Receptor	Inflammation/Immunology Endocrinology
Bamirastine inhibits ligand binding to recombinant human histamine H₁ receptors (rhH₁R) with an IC₅₀ value of 17.3 nM.

HY-164552

ZNU-IMB-Z15	Apoptosis Androgen Receptor	Cancer
ZNU-IMB-Z15 (Compound Z15) is an antagonist of the androgen receptor (AR) and also a selective degrader of AR and ARV7. ZNU-IMB-Z15 can directly bind to the ligand-binding domain (LBD) and activation function-1 region of AR, and promote AR degradation through the proteasome pathway. ZNU-IMB-Z15 effectively inhibits the transcriptional activity of AR, AR mutants, and AR splice variants (ARVs), downregulating the mRNA and protein levels of AR downstream target genes, thereby overcoming the resistance to second-generation antiandrogen drugs induced by AR LBD mutations, AR amplification, and ARVs in castration-resistant prostate cancer (CRPC). ZNU-IMB-Z15 can inhibit the proliferation of AR-positive CRPC cell lines and induce their apoptosis, demonstrating anticancer activity both in vivo and in vitro .

HY-159922

AR antagonist 9	Androgen Receptor	Cancer
AR antagonist 9 is an orally bioavailable selective androgen receptor (AR) antagonist that exerts anticancer effects by disrupting the dimerization of AR ligand-binding domains, showing potential for overcoming drug resistance in prostate cancer (PCa). Its AR antagonistic activity has an IC₅₀ value of 0.051 μM, comparable to Enzalutamide (HY-70002) (IC₅₀ = 0.060 μM). AR antagonist 9 demonstrated superior efficacy against AR_F876L/T877A and AR_W741C mutants compared to Enzalutamide (HY-70002). Furthermore, AR antagonist 9 exhibited favorable pharmacokinetic properties, with an oral bioavailability of F = 66.24% in rats. In the LNCaP xenograft mouse model, oral administration of AR antagonist 9 significantly inhibited tumor growth. AR antagonist 9 holds promise for research into overcoming PCa drug resistance .

HY-119782

L-Argininamide	Fluorescent Dye	Others
L-Argininamide is a hydrophilic amino acid derivative and can be used as a compound for *ligand* binding DNA aptamers. L-Argininamide has the potential for fluorescent aptasensors development .

HY-D1398

LtIA-F	nAChR	Neurological Disease
LtIA-F, a novel fluorescent analogue of LtIA, provides a wealth of pharmacological tools to explore the structure–function relationship, distribution, and ligand binding domain of the α3β2 nAChR subtype.

HY-135345

PROTAC FKBP Degrader-3 1 Publications Verification	PROTACs FKBP	Cancer
PROTAC FKBP Degrader-3 is a PROTAC that comprises a FKBP ligand binding group, a linker and an von Hippel-Lindau binding group. PROTAC FKBP Degrader-3 is a potent FKBP degrader .

HY-130714

TD-165 1 Publications Verification	PROTACs	Cancer
TD-165 is a PROTAC-based cereblon (CRBN) degrader. TD-165 comprises a?cereblon (CRBN)?ligand binding group, a linker and an?von Hippel-Landau (VHL)?binding group .

HY-128845

PROTAC CRBN Degrader-1	PROTACs	Cancer
PROTAC CRBN Degrader-1 comprises a cereblon (CRBN) ligand binding group, a linker and an von Hippel-Landau (VHL) binding group. PROTAC CRBN Degrader-1 is an cereblon (CRBN) degrader .

HY-NP002B

Rabbit Serum Albumin	Biochemical Assay Reagents	Others
Rabbit Serum Albumin is a plasma protein derived from rabbits. Serum albumin is a multifunctional protein with extraordinary ligand binding capacity, making it a transporter molecule for a diverse range of metabolites, drugs, nutrients, metals and other molecules .

HY-NP002A

Goat Serum Albumin	Biochemical Assay Reagents	Others
Goat Serum Albumin is a plasma protein derived from goats. Serum albumin is a multifunctional protein with extraordinary ligand binding capacity, making it a transporter molecule for a diverse range of metabolites, drugs, nutrients, metals and other molecules .

HY-NP002I

Sheep Serum Albumin	Biochemical Assay Reagents	Others
Sheep Serum Albumin is a plasma protein derived from sheep. Serum albumin is a multifunctional protein with extraordinary ligand binding capacity, making it a transporter molecule for a diverse range of metabolites, drugs, nutrients, metals and other molecules .

HY-NP002C

Rabbit Serum Albumin (globulin free)	Biochemical Assay Reagents	Others
Rabbit Serum Albumin (globulin free) is a plasma protein derived from rabbits. Serum albumin is a multifunctional protein with extraordinary ligand binding capacity, making it a transporter molecule for a diverse range of metabolites, drugs, nutrients, metals and other molecules .

HY-23999

BI-0115	LOX-1	Cardiovascular Disease
BI-0115 is a selective inhibitor of LOX-1 (IC₅₀=5.4 µM) that blocks cellular uptake of oxLDL. BI-0115 binding triggers receptor inhibition by formation of dimers of the homodimeric ligand binding domain .

HY-120210

XY018	ROR	Inflammation/Immunology Cancer
XY018 is a potent ROR-γ-selective antagonist. XY018 inhibits ROR-γ constitutive activity in 293T cells with high potency (EC₅₀, 190 nM). XY018 binds to the ROR-γ hydrophobic ligand binding domain (LBD) .

HY-128839

PROTAC ERRα Degrader-2	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ERRα Degrader-2 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha (ERRa) binding group. PROTAC ERRα Degrader-2 is an estrogen-related receptor alpha (ERRa) degrader .

HY-110392

CMP8	Estrogen Receptor/ERR	Cancer
CMP8, a selective ligand for estrogen receptor, binds to the mutant estrogen receptor ligand binding domain (ERLBD). CMP8 exhibits IC₅₀ values of 29 nM , 41 nM, 1100 nM and 2200 nM for MGERα, MGRERα, hERα and hERβ, respectively .

HY-128838

PROTAC ERRα Degrader-1	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ERRα Degrader-1 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha (ERRa) binding group. PROTAC ERRα Degrader-1 is an PROTAC estrogen-related receptor alpha (ERRa) degrader .

HY-P9977

Amivantamab 1 Publications Verification JNJ-61186372	EGFR	Cancer
Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .

HY-109176

Giredestrant 5 Publications Verification GDC-9545; RG6171	Estrogen Receptor/ERR	Cancer
Giredestrant (GDC-9545), a non-steroidal estrogen receptor (ER) ligand, is an orally active and selective ER antagonist. Giredestrant potently competes with Estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity .

HY-NP002D

Bovine Serum Albumin (Biotinylated)	Biochemical Assay Reagents	Others
Bovine Serum Albumin (Biotinylated) is a biotinylated bovine serum albumin that selectively binds to different vascular subsets in lymphoid tissue. Serum albumin is a multifunctional protein with extraordinary ligand binding capacity, making it a transporter molecule for a diverse range of metabolites, drugs, nutrients, metals and other molecules .

HY-135903

Giredestrant tartrate GDC-9545 tartrate; RG6171 tartrate	Estrogen Receptor/ERR	Cancer
Giredestrant tartrate (GDC-9545 tartrate), a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist. Giredestrant tartrate potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Anti-tumor activity .

Cat. No.	Product Name

HY-L152

F-Fragments Library

5,074 compounds

19F-NMR has proved to be a detection mode in fragment-based drug discovery (FBDD) for studies of protein structure and interactions. 19F shows high sensitivity for NMR detection, and the exquisite sensitivity of 19F chemical shifts and linewidths to ligand binding all make it a valuable approach in FBDD.F (Fluorine) -Fragments can be used for 19F-NMR detection after binding to target proteins, and can be used as an effective 19F-NMR tool for FBDD.

MCE designs a unique collection of 5,074 F-fragments, all of which obey a heuristic rule called the “Rule of Three (RO3)”, in which molecular weight ≤300 Da, the number of hydrogen bond donors (H-donors) ≤3, the number of hydrogen bond acceptors (H-acceptors) is ≤3 and cLogP is ≤3. This F-fragments library is an important source of lead-like drugs.

Cat. No.	Product Name	Type